Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its po.

Business Wire • Nov 14, 2025

Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of le.

Business Wire • Nov 12, 2025

Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript

Sensus Healthcare, Inc. ( SRTS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Joseph Sardano - Co-Founder, Chairman & CEO Michael Sardano - President, General Counsel, Corporate Secretary & Director Javier Rampolla - Chief Financial Officer Conference Call Participants Tirth Patel - Lippert/Heilshorn & Associates, Inc. Anthony Vendetti - Maxim Group LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and welcome to the Sensus Healthcare Third Quarter 2025 Financial Results Conference Call.

Seeking Alpha • Nov 7, 2025

Sensus Healthcare Reports Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025. Highlights of the third quarter of 2025 and subsequent weeks include the following: CMS established coding validating SRT for treating non-melanoma skin cancer Revenu.

Business Wire • Nov 6, 2025

Sensus Healthcare, Inc. (SRTS) Reports Q3 Loss, Tops Revenue Estimates

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Nov 7, 2025

Sensus Healthcare Named to TIME's America's Growth Leaders of 2026

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that it has been named to TIME's list of America's Growth Leaders of 2026, developed in partnership with Statista Inc. The ranking recognizes 500 U.S. publicly traded companies characterized by revenue growth, financial stability and.

Business Wire • Nov 6, 2025

CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC). SRT-dedicated CPT codes refle.

Business Wire • Nov 4, 2025

Sensus Healthcare Announces the Passing of Director Bill McCall

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the passing of longtime friend of the Company and current Director William “Bill” McCall. Bill's involvement with Sensus dates to 2009, when he played a key role in transforming the company from concept to reality. He led the Company's ini.

Business Wire • Oct 31, 2025

Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6

BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer q.

Business Wire • Oct 23, 2025

Sensus Healthcare, Inc. (SRTS) Falls More Steeply Than Broader Market: What Investors Need to Know

Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $3.31, moving 4.06% from the previous trading session.

Zacks Investment Research • Oct 16, 2025